Aim We aimed to assess the clinicopathological relevance and prognostic significance of expression of the hepatic progenitor cell markers keratin 19 (K19), epithelial cell adhesion molecule (EpCAM) and CD117 (c-KIT) in a White series of hepatocellular carcinoma (HCC). Methods We evaluated the immunohistochemical expression of K19, EpCAM and CD117 in 89 surgical specimens of HCC from Greek patients (mean age 66.7 ± 11.3 years, male 75.2%) followed up for 39.6 ± 25.3 months. Results K19, EpCAM and CD117 expression was detected in tumour cells of 10.11, 15.38 and 3.7% HCCs, respectively. Female sex was correlated with EpCAM immunohistochemical expression (P = 0.035), whereas no other significant relationship with clinicopathological parameters was observed. K19 positivity tended to be correlated with microvascular invasion (P = 0.054). In univariate analysis, K19 positivity and microvascular invasion were found to be associated with decreased recurrence-free survival (P < 0.001 and P = 0.004, respectively) and overall survival (P = 0.002 and P = 0.029, respectively). EpCAM and CD117 positivity was not correlated with patient survival. In multivariate analysis, K19 positivity emerged as an independent predictor of recurrence-free survival (odds ratio = 7.84, 95% confidence interval = 2.658-22.912, P < 0.001) and overall survival (odds ratio = 3.845, 95% confidence interval = 1.401-10.549, P = 0.009).
Introduction
Hepatocellular carcinoma (HCC) is a neoplasm of increasing incidence and is the third most common cause of cancer-related death worldwide [1] . HCC is currently considered a heterogeneous entity because of substantial differences in molecular profile and biological behaviour. HCC diversity also refers to the cells of origin, as mature hepatocytes as well as hepatic progenitor cells (HPCs) may be the target population in hepatocarcinogenesis within the context of advanced liver disease and cirrhosis [2] . Direct proof that primary liver carcinomas with mixed features derive from HPCs/oval cells originates only from rodent studies [3] , whereas indications from human studies were until recently limited and/or speculative. The strongest evidence to date that liver malignancy in humans may derive from HPCs has been the demonstration of HPC/stem cell marker expression in HCC and the associated worse patient prognosis [4, 5] .
Carcinomas of HPC origin and their subtypes are grouped together in the category of combined hepatocellular-cholangiocarcinoma according to the WHO 2010 classification of liver tumours [6] . Another recently proposed HCC subtype of assumed HPC origin is emerging, defined by the presence of a tumour cell fraction expressing HPC markers, but not otherwise recognizable by routine haematoxylin-eosin staining [7] . Several markers, including keratin 19 (K19), epithelial cell adhesion molecule (EpCAM), CD133, CD117 (c-KIT) and SALL4 have been suggested as indicators of HPC origin in HCCs [8] . K19, normally found in HPCs and cholangiocytes but not in hepatocytes, has been proven to be the most reliable marker for the characterization of HPCs [9, 10] . Markers of stemness have been associated with increased telomere length and chromosomal instability [11] , microvascular invasion [12] , high metastatic potential [13] and poor survival [14] [15] [16] . There is also increasing evidence suggesting that K19 immunohistochemical expression may be used as a prognostic marker in human HCC [10, 14, [17] [18] [19] [20] [21] [22] . However, the majority of these studies are based on HCCs of Asian origin. HCCs with a K19-expressing cell population are not as yet an established entity, whereas controversial data on biological behaviour require further investigation at the clinicopathological and molecular levels.
Similarly, EpCAM represents a marker of stem cells/ progenitor cells of the adult human liver and oval cells of the rodent liver and can be used to classify HCCs according to tumour aggressiveness. EpCAM expression has been shown to be associated with worse outcomes following liver transplantation [23] or resection [9, 24, 25] . Although no association has so far been established between CD117 expression and poor prognosis, CD117 has also been considered as a potential marker of stem/ progenitor cells in previous HCC studies [26] [27] [28] [29] [30] .
The objective of the present study was to examine K19, EpCAM and CD117 expression in a series of human HCCs of White origin and their potential correlation with clinicopathological parameters and patient prognosis after curative liver resection or transplantation.
Methods
We retrospectively identified all HCC cases (explant livers and resection specimens) from the archives of the 1st Department of Pathology and the Laboratory of Histology-Embryology, Medical School, National and Kapodistrian University of Athens, between June 1996 and March 2009. We subsequently sought clinical details of these patients through their medical notes, including treatment received and overall survival (OS). In total, 113 patients with histologically diagnosed HCC were identified; among these patients, 89 had sufficient clinical data and were included in the study. Clinical parameters of the study population were retrospectively collected. The mean patient age was 66.7 11.3 years (range 33-85), and 75.2% of patients were male.
Data on the aetiology of the underlying chronic liver disease were available in 72 cases and included hepatitis B virus infection (n = 30/72, 41.7%), hepatitis C virus infection (n = 21/72, 29.2%), alcohol-related steatohepatitis (n = 4/72, 5.6%) and nonalcoholic steatohepatitis (8/72, 11.1%). Hepatitis B and C coinfection was present in 5/72 cases (6.9%). Other aetiologies included haemochromatosis (n = 2) and primary biliary cirrhosis (n = 2). In 17 cases, the underlying aetiology could not be established. Cirrhosis was present in 46 out of the 73 (63%) patients, with background non-neoplastic tissue available for analysis. Thirteen patients received locoregional treatment before resection or transplantation [transarterial chemoembolization (TACE), n = 12; radiofrequency ablation (RFA), n = 1].
Pathological variables recorded included tumour size, presence of multiple tumours, tumour grading according to Edmondson and Steiner [31] , capsular invasion, microvascular and/or macrovascular invasion and the presence of cirrhosis in the non-neoplastic liver parenchyma. Staging was performed according to tumour, node, metastasis (TNM) classification (7 th edition) [32] .
The study was performed in accordance with National Bioethical Standards and ethical standards of the revised Helsinki Declaration of the World Medical Association (2000) . Appropriate consent for use of anonymized archival tissue for research was obtained in each case.
Immunohistochemistry
Formalin-fixed, paraffin-embedded 4-μm-thick serial tissue sections of each case were preheated at 56°C, deparaffinized in xylene, rehydrated in graded ethanol and then washed in PBS (pH = 7.6). Heat-induced antigen retrieval was performed with 10 mmol/l citrate buffer (pH 6.0) for 12 min (for K19 and EpCAM) or with EDTA (pH = 9) for 8 min (for CD117) in a microwave oven (600 W). Immunohistochemical analysis was carried out using the NovoLink Polymer Detection System (Novocastra Laboratories-Menarini, Athens, Greece) and mouse monoclonal antibodies to K19 (clone A53-B/A.2.26; Thermo Scientific, East Grinstead, UK; 1/50 dilution), EpCAM (ESA Ab-7, MOC31; Neomarkers, Freemont, California, USA; 1/50 dilution), and CD117 (clone 2E4; Zymed, San Francisco, California, USA; 3/100 dilution), with overnight incubation at 4°C. 3′,3′-Diaminobenzidine was used as a chromagen and light haematoxylin as a counterstain.
Cholangiocytes in non-neoplastic liver parenchyma present in most sections served as an internal positive control for K19 and EpCAM, whereas mast cells were used as an internal positive control for CD117. In negative control sections of each case, the primary antibody was omitted and replaced with an antibody diluent (RE7133; Novocastra Laboratories, UK) compatible with the immunohistochemical kit used.
Evaluation of immunohistochemical staining
Immunostained sections were evaluated by two observers (D.T., J.D.), blinded to the clinical and follow-up data, under a double-headed microscope. Positivity for K19, EpCAM or CD117 was defined as specific cytoplasmic and/or membrane immunostaining in at least 5% of tumour cells [14, 15, 21, 22, 33] . Immunopositive ductular cells, isolated or in strings, originating from surrounding non-neoplastic liver parenchyma and localized at the tumour periphery ( Fig. 1) were not counted.
Follow-up
Sixty-eight out of 89 patients were followed up until the date of HCC-related death or until the end of follow-up (31 January 2011). The remaining 21 patients were lost to follow-up. Patients who underwent liver transplantation (n = 9) were censored as alive on the day of transplantation. The mean follow-up period was 39.6 25.3 months (median 33 months).
Statistical analysis
Statistical analysis was carried out with SPSS software, version 19.0 (SPSS Inc., Chicago, Illinois, USA), using the t-test, Pearson's correlation test, or the χ 2 -test, as deemed appropriate. Data were reported as mean SD if normally distributed and as median if not. Recurrence-free survival (RFS) and OS were calculated using the Kaplan-Meier method, and differences in the survival rate were compared using the log-rank test. Deaths from causes other than HCC were not considered for inclusion in survival analysis. Multivariate analysis for OS and RFS was carried out using the Cox-proportional hazards model with backward stepwise selection. Statistical significance was assumed at P less than 0.05.
Results

Clinical and pathological features of the study population
Data on some clinicopathological features were not available for all HCC cases (Table 1) . Multinodular HCC (three or more nodules) was present in 20/75 (26.7%) cases, whereas 37/72 (51.4%) cases had a maximum tumour diameter greater than 5 cm. Microvascular invasion was observed in 39/70 HCCs (55.7%) and 18/47 HCCs (38.3%) showed portal vein thrombosis either on imaging or at the time of operation. Accordingly, in 27/54 (50%) and 8/56 (14.3%) HCCs, liver capsule invasion or rupture was observed. Distant metastasis was recorded in 6/36 (16.7%) patients. Postsurgical staging according to TNM classification was as follows: stage I: 24 patients, II: 15 patients, III: 32 patients (IIIa: 23 patients, IIIb: six patients, IIIc: three patients), IV: six patients. In 12 patients, TNM staging could not be assessed because of missing data.
Correlation with clinicopathological parameters Keratin 19 K19 was positive in 9/89 HCCs (10.11%; Fig. 2a and c). K19 immunostaining was observed in the cell membrane and/or the cytoplasm of positive tumour cells. The percentage of K19-positive tumour cells ranged from 5 to 90% (mean 24.4 32.54%, median 5%; Fig. 3b ) and immunostaining was focal in the majority of cases (7/9). Only 3/9 K19-positive HCCs focally showed positive tumour cells with morphological features suggestive of stem/progenitor cells (small, hyperchromatic nuclei and scant cytoplasm). Distinctive histological patterns of HCC (trabecular, solid, pseudoglandular, clear cell, etc.) did not correlate with K19 positivity. In K19-positive HCC with microvascular invasion, when intravascular tumour cells were included in the immunostained sections, these were also K19 positive.
Age, sex, tumour size greater than 5 cm, histological grade, TNM stage, presence of cirrhosis, multinodular disease, and viral aetiology were not significantly correlated with K19 protein expression (P > 0.05). Of all the parameters examined, only microvascular invasion tended to be correlated with K19 immunohistochemical expression (P = 0.054; Table 1 ). There were no statistical differences between HCC subgroups with focal and those with diffuse K19 positivity.
EpCAM
EpCAM expression was assessed in 78 HCC cases with tissue available for immunostaining ( Fig. 2b and d ). EpCAM was positive in 12/78 HCCs (15.38%; Fig. 2b ). EpCAM-specific immunostaining was membranous in positive tumour cells. The percentage of EpCAM-positive tumour cells ranged from 26 to 90% (mean 58.17 25.7, median 58.5%; Fig. 3c ), and immunostaining was diffuse in the majority of cases (9/12). Two out of 12 EpCAMpositive HCCs focally showed positive tumour cells, with morphological features suggestive of stem cells. Distinctive histological patterns of HCC did not correlate with EpCAM positivity. In EpCAM-positive HCC with microvascular invasion, when intravascular tumour cells were included in the immunostained sections, these were also EpCAM positive. The correlation between EpCAM expression and clinical or pathological parameters was examined (Table 1) . Age, tumour size greater than 5 cm, histological grade, presence of cirrhosis, multinodular disease and viral aetiology showed no correlation with EpCAM protein expression (P > 0.05). Of all parameters examined, only female sex was significantly correlated with EpCAM immunohistochemical expression (P = 0.035). Three cases were positive for both K19 and EpCAM, nine were K19-negative/EpCAM-positive, five were K19-positive/ EpCAM-negative, and 61 were negative for both markers. In serial sections of K19-positive/EpCAM-positive HCCs, more tumour cells were positive for EpCAM compared with K19 ( Fig. 2a and b ). Coexpression of K19 and EpCAM occurred in a minority of tumour cells, whereas the majority expressed only one of the two markers.
CD117
CD117 was positive only in 3/81 (3.7%) cases in the cytoplasm of a small percentage of tumour cells (5%; Fig. 3d ). Rare CD117-positive tumour cells showed morphological features of stem cells. CD117 immunopositivity did not show significant correlation with any of the clinicopathological parameters examined (P > 0.05; Table 1 ). Two grade 3 CD117-positive HCC cases had multifocal disease with vascular invasion (portal vein thrombosis) and none of the cases had distant metastasis. One grade 3 HCC showed coexpression of K19 and CD117, and one grade 2 HCC showed coexpression of EpCAM and CD117.
Survival analysis
During follow-up, 43 out of 68 (63.2%) patients had recurrent disease and 28/68 (41.2%) died of HCC-related causes. Two patients with K19-positive HCC were lost to follow-up. Among the remaining seven patients with K19-positive HCC and complete follow-up data, six had tumour recurrence and six (85.7%) died. Patients with K19-positive HCC had a significantly decreased mean RFS (P < 0.001) and OS (P = 0.002; Fig. 4 ) compared with those with K19-negative HCC. EpCAM or CD117 positivity did not show any significant correlation with either RFS or OS. When K19 and EpCAM coexpression was examined, patients with K19-positive/EpCAM-positive HCC were characterized by significantly decreased RFS (P < 0.001) and OS (P = 0.001) compared with those with K19-negative/EpCAM-negative HCC. Although the numbers are very small to draw robust conclusions, it is of interest that patients with HCC showing K19 and EpCAM coexpression (n = 3) had worse median RFS and median OS times compared with patients with HCC exhibiting only K19 positivity (n = 5; log-rank test, P = 0.006 and P = 0.001, respectively).
Univariate analysis
On univariate analysis, microvascular invasion (P = 0.004; Fig. 5 ) and advanced TNM stage (≥ III; P =0.047) were found to be significantly correlated with decreased RFS. There was no relationship between tumour size greater than 5 cm (P = 1.00), histological grade of 3 or higher (P = 1.00), previous treatment (TACE or RFA; P = 0.133) and RFS. The presence of microvascular invasion was significantly associated with OS (P = 0.029; Fig. 5 ). Tumour size greater than 5 cm (P = 0.56), advanced histological grade (P = 0.95), TNM stage of at least III (P = 0.089) and previous treatment (TACE or RFA; P = 0.635) were not significantly correlated with OS.
Multivariate analysis
All variables that showed significant correlation with OS and RFS were included in the multivariate model-building strategy. Cox-regression analysis revealed that K19 positivity was independently associated with RFS (odds ratio = 7.84, 95% confidence interval = 2.658-22.912, P < 0.001), whereas the presence of microvascular invasion and TNM stage of at least III did not show independent associations with RFS (Table 2) . Similarly, K19 positivity was the only independent prognostic factor of OS (odds ratio = 3.845, 95% confidence interval = 1.401 -10.549, P = 0.009; Table 3 ).
Discussion
It is a well-established theory that human HCCs usually emerge during the process of multistep carcinogenesis [34] . Mature hepatocytes may transform, creating premalignant lesions, namely dysplastic foci and dysplastic nodules, that give rise to well-differentiated early-stage HCCs (early HCCs) [35] . Moreover, there is growing evidence that some HCCs derive from HPCs [34] . Primary liver carcinomas of the combined type (combined HCC and cholangiocarcinoma) and HCCs that express progenitor cell markers are now recognized as examples of such alternative carcinogenic pathways [5, 36] . Two different theories have so far been expressed with regard to the presence of progenitor cell features in a tumour. Either the cell of origin is a progenitor cell (maturation arrest theory) or, alternatively, tumours dedifferentiate and acquire progenitor cell features during carcinogenesis (dedifferentiation theory) [7, [37] [38] [39] . The presence of progenitor cells in early premalignant lesions, such as dysplastic foci, is a strong argument in favour of a progenitor cell origin as opposed to dedifferentiation at a later stage [38] .
The adverse prognosis of HCCs expressing HPC/stem cell markers may partly be attributed to the relationship between this subset of HCCs with invasion-related and metastasis-related gene expression. Upregulation of invasion-related and metastasis-related genes, such as epithelial-mesenchymal transition genes [7, 9] , VIL2 (encoding ezrin) [7, 40] , PLAUR (urokinase plasminogen activator receptor) [7] and CD44 [7] , has been demonstrated in HCCs with HPC features. Moreover, an association between high expression levels of HPC markers in HCCs and tumour angiogenesis has recently been reported [4] . HCCs expressing 'stemness'-related proteins are also characterized by increased telomere length, increased expression of human telomerase reverse transcriptase and shelterin complex proteins, and increased chromosomal instability compared with conventional HCCs, as shown in a recent study [11] .
There are strong indications that K19 may be used as an HPC marker of prognostic significance [10, 17, 18] . Recently, a progenitor cell-derived HCC model was established in rats, which was characterized by a K19-positive gene signature that accurately predicted tumour recurrence and patient survival in human HCC [3] . Along these lines, an extensive gene-expression profiling study demonstrated the presence of a 'hepatoblast subtype' of human HCCs characterized by K19 expression [4] . There is growing evidence that K19 positivity is associated with increased expression of invasion-related proteins, both at protein and mRNA levels [9, 19] . It still remains uncertain whether K19 expression implies that K19-positive HCCs actually carry stemness functions, as shown for the K19-positive ductular reactions of the regenerating liver, or whether this expression is merely an epiphenomenon of poor differentiation [39] .
Several studies have reported K19 protein expression in HCCs varying from 4.1 to 22.1% [5, 9, [12] [13] [14] [15] 17, 20, 22, 36, 39, [41] [42] [43] [44] [45] [46] . K19 expression has been correlated with poor histological differentiation [14, 15, 20] , macrovascular and microvascular invasion [5, 9] , advanced tumour stage and lymph node metastasis [13] . RFS and OS of patients with K19-positive HCC have been shown to be reduced following surgical resection [4, 21] , radiofrequency ablation [43] and liver transplantation [22] . In addition, K19 immunopositivity in needle biopsies of HCCs has been recently identified as an independent predictor of overall patient survival [46] . There is limited evidence indicating increased resistance to chemotherapy in HCCs that express HPC markers, including K19 [45] .
In our study, the expression of K19, EpCAM and CD117 was examined in a series of HCCs with a high incidence of hepatitis B virus infection, which remains a major aetiological factor of chronic liver disease in the Greek population [47] . The expression of K19 in our study group was 10.11%, and it showed no correlation with baseline characteristics such as tumour size, background chronic liver disease aetiology and histological grade. Among the baseline tumour characteristics, microvascular invasion was the only parameter that tended to be correlated with K19 tissue expression, a finding that is concordant with previous evidence on the positive correlation of K19 expression with tumour angiogenesis and invasion [5, 9, 19] . The correlation of K19 with microvascular invasion did not reach statistical significance (P = 0.054), most likely because of a type II statistical error; examining a larger number of HCCs could have shown a significant association. In univariate analysis, advanced TNM stage was found to be correlated with RFS, whereas microvascular invasion was found to be correlated with both RFS and OS. However, multivariate analysis indicated that K19 positivity was the only independent prognostic factor for both OS and RFS. Our findings highlight the prognostic importance of K19 positivity in a White patient cohort, as most relevant data to date come from Asian studies [5, 9, [12] [13] [14] 17, 20, 36, 39, [42] [43] [44] [45] , and are in keeping with those of a recent prospective study from Belgium on K19 immunohistochemical expression in 242 HCCs from White patients [19] .
Similarly, EpCAM has previously been identified as a marker of oval cells in the rodent liver and of stem/progenitor cells in the adult human liver [25, 33, [48] [49] [50] [51] [52] [53] . Recent studies, have shown that isolation of EpCAM( + ) tumour cells from peripheral blood is strongly correlated with prognosis in patients with HCC [54, 55] . In a study by Yamashita et al. [33] , expression of EpCAM and α-fetoprotein (AFP) was used to classify HCCs in four different subtypes with different prognoses and specific activated pathways depending on tumour cell origin. The categories proposed were EpCAM( + )/AFP( + ) HCC as hepatic stem cell-like HCC (HpSC-HCC), EpCAM( + )/AFP(− ) HCC as bile duct epithelium-like HCC, EpCAM(− )/AFP( + ) HCC as hepatocyte progenitor-like HCC, and EpCAM(− )/AFP (− ) HCC as mature hepatocyte-like HCC (MH-HCC). The same study showed that other HPC markers such as K19 and CD117 were more abundantly expressed in HpSC-HCC. EpCAM( + )/AFP( + ) HCCs (HpSC-HCC) were characterized by poor prognosis, whereas EpCAM ( + )/AFP(− ) HCCs (MH-HCC) exhibited more favourable outcomes. In our study, isolated EpCAM expression was not significantly correlated with patient RFS or OS. This finding corroborates previous data showing that EpCAM expression is present in both hepatic stem-like and mature hepatocyte-like HCCs that are characterized by opposing clinical outcomes [33] . In our series K19/EpCAM coexpression in HCC was associated with worse RFS and OS compared with that in patients with HCCs expressing K19 alone. However, this finding needs to be further assessed in a larger number of HCCs, as in our study group K19/ EpCAM coexpression was only seen in 3/78 HCCs. CD117 was only expressed in a small percentage of tumour cells in only 3.7% of HCCs and showed no significant association with prognostic features.
In conclusion, our study showed that K19 immunopositivity is an independent predictor of RFS and OS in a cohort of Greek patients with HCC and could be used to stratify HCC according to tumour aggressiveness. Our study supports the prognostic role of K19 independently of other clinicopathological parameters. Inclusion of K19 expression, as a marker of tumour aggressiveness in HCC, independently of tumour grade and stage, may increase the predictive value of the currently used scoring systems. The recent association between K19 expression and the epidermal growth factor receptor pathway in HCC [44] suggests a possible role for therapeutic use of epidermal growth factor receptor inhibitors and may open the way for a more personalized treatment approach in HCC patients.
